New cancer drug interaction study recruits healthy volunteers

NCT ID NCT07395024

Recruiting now Knowledge-focused Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how three common medicines—fluconazole, itraconazole, and carbamazepine—change the way the body processes a new experimental drug called ASP3082. ASP3082 is being developed for cancers with a specific KRAS mutation. The trial involves 54 healthy adults split into three groups, each receiving ASP3082 alone and then with one of the other drugs. The main goal is to measure drug levels in the blood and check for side effects, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Setidegrasib (ASP3082) given intravenously, plus oral fluconazole, itraconazole, or carbamazepine
What this could lead to: If successful, this study will show how other drugs affect ASP3082 levels in the body, helping guide safe dosing for future cancer trials.
What could go wrong: This is a very early phase 1 study in healthy volunteers, not patients. It only measures drug levels and safety, not whether ASP3082 works against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Parexel
RECRUITING

Baltimore, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.